Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Announcement of a Change in Shareholding According to Chapter 9, Section 10 of the Finnish Securities Market Act

Sitowise Group Plc Stock Exchange Release 16 October 2024 at 12.30 p.m. (EEST) Sitowise Group Plc (the "Company") has on 15 October 2024 received a notification in accordance with the Chapter 9, Section 10 of the Finnish Securities Market Act from Morgan Stanley, according to which Morgan Stanley & Co International Plc's holding of the shares and votes of the Company has increased to 11.16 percent on 14 October 2024. According to the notification, Morgan Stanley holds indirectly a total of 2,920,915 shares corresponding to 8.15 percent of the Company’s shares and votes, and a total of

BioStock: Prolight eyes business opportunity for plasma separation method

Prolight Diagnostics has secured European patent approval for its method for separating plasma from whole blood, utilized in the MicroFlex system. This separation technology presents a business opportunity as it can be integrated into other systems and adapted for use with various sample types. To gain deeper insights into the technology, BioStock contacted the company’s development partner, TTP.Read the full article at biostock.se :https://www.biostock.se/en/2024/10/prolight-eyes-business-opportunity-for-plasma-separation-method/ This is a press release

Profit warning, inside information: UPM lowers its outlook due to lower deliveries in most businesses and decreased pulp prices

UPM-Kymmene Corporation Stock Exchange Release (Inside information) 16 October 2024 at 12:00 EEST Profit warning, inside information: UPM lowers its outlook due to lower deliveries in most businesses and decreased pulp prices UPM lowers its outlook for 2024 and releases its preliminary Q3 2024 results. During the second half of the year, UPM’s earnings have improved, however less than earlier expected. Comparable EBIT in Q3 2024 increased by 32% to EUR 291 million from Q3 2023, and 17% for the first nine months compared to last year. Comparable EBIT in Q4 2024 is expected to be on

Arctic Bioscience – Mandatory notification of trade

Gold Coast Nutrition, a legal person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has today bought 5,000 shares in Arctic Bioscience at an average price of NOK 3,00 per share. Following the transaction, Gold Coast Nutrition holds 460,000 shares in Arctic Bioscience.CSO at Arctic Bioscience, Hogne Hallaråker, is the owner of Gold Coast Nutrition. Please refer to the attached notification of trading for further details.  This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19 and the

Outokumpu publishes its January-September interim report and arranges a webcast on October 30, 2024

Outokumpu CorporationPress releaseOctober 16, 2024 at 11.00 am EESTOutokumpu will publish its interim report for January-September 2024 on Wednesday, October 30, 2024 at approximately 9.00 am EET. A live webcast and conference call to analysts, investors and representatives of media will be arranged later on the same day, at 3.00 pm EET at https://outokumpu.videosync.fi/q3-2024 hosted by President and CEO Kati ter Horst and CFO Marc-Simon Schaar. To ask questions, please participate in the conference call by registering at https://palvelu.flik.fi/teleconference/?id=50049025. After

Cessatech announces that recruitment has today reached the halfway point for patient recruitment with 75 included patients in the Paediatric Study 0202

· 75 paediatric patients have now been recruited in Study 0202 · Study 0202 is the final required clinical study that will evaluate the safety and efficacy profile for CT001 in children · CT001 is a nasal spray for the treatment of acute pain in childrenOn 16 October – Cessatech A/S (“Cessatech” or “the Company”) announces that it has reached the halfway point for patient recruitment of its final study Paediatric Study 0202 in the development program of 0202. Study 0202 is the final required clinical study that will evaluate the safety and efficacy profile for CT001 in 150 children.

CasinoRank Launches New Podcast "iGaming Pulse" – Your Source for iGaming News and Trends

Stockholm, October 16, 2024 – CasinoRank is excited to introduce iGaming Pulse, a brand-new podcast created to keep listeners informed about the latest news, trends, and developments in the iGaming industry. Whether you're a gaming enthusiast or someone working within the industry, iGaming Pulse delivers straightforward, engaging conversations and expert insights that are easy to follow.Although the podcast has just launched, iGaming Pulse is set to grow rapidly, with plans to expand into more topics and feature a broader range of expert interviews. In each episode, listeners can expect

Salsa to Present Award-winning Tech Solutions for Latam’s Regulated Markets at SBC Summit Latinoamérica

Salsa Technology is heading to SBC Summit Latinoamérica where it will be available to present its solutions that are already active and producing results in the regulated Brazilian market. The special event is being held between October 29th and October 31st at the Seminole Hard Rock Hotel & Casino and is a must for those companies seeking to expand their reach in the region.An integral part of Salsa’s LatAm-focused solutions is the innovative Salsa Omni (PAM) platform, certified by GLI. With its robust and comprehensive back office, it provides an unmatched level of autonomy for operators

Big Akwa Opens new Investment Round to Drive the Future of circular foodproduction

Big Akwa, a Swedish food-tech company developing a land-based aquaculture project with an annual capacity of 6000 tons at Alby industrial park in mid Sweden, announces the opening of new investment round.The raised capital will be used to continue the development of the planned facility and support the company’s growth strategy. “We look forward to welcoming new and existing investors to join our journey towards efficient and circular food production” says Elena Petukhovskaya, CEO and co-founder. For more information, please contact: Elena Petukhovskaya, CEO Big Akwa AB (publ.)

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 230 – 16 OCTOBER 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 171/24 and 173/24, respectively. Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Martin Badsted, Chief Financial Officer, tel.: +45 33 42 05 26, e-mail: mba@norden.com

Akastor ASA: Invitation to Presentation of Third Quarter 2024 Results

Akastor ASA invites investors and analysts to a webcast presentation of the third quarter 2024 financial results on Wednesday, 30 October 2024. Date and time:Wednesday, 30 October 2024, at 15:00 CET Presenters: · Akastor: Karl Erik Kjelstad, CEO, and Øyvind Paaske, CFO · HMH: Thomas McGee, CFO, and David Bratton, SVP FP&A and Operational Finance Link to webcast:https://akercreativehub.eventcdn.net/events/akastor-audiocast-q3-2024 Questions can be submitted throughout the streaming event. The presentation material will be published on www.akastor.com and www.newsweb.

Brödernas applies for company restructuring

Stockholm 16 October 2024 Restaurant group Brödernas has today applied for company restructuring in order to secure the group’s future. During the restructuring process, Brödernas’ restaurants will be open as normal. Brödernas, including Brödernas Group AB (publ), has today applied for company restructuring. The purpose of the restructuring is to secure the group’s long-term financial stability and handle the economic challenges that have emerged in the wake of inter alia the pandemic, inflation, increased interest rates and increased rental costs. Brödernas’ application for

Notice to attend the Extraordinary General Meeting in Metacon AB (publ)

The English text is an unofficial translation. In case of discrepancies between the Swedish language version of this document and the English translation, the Swedish language version shall prevail. The shareholders in Metacon AB (publ), reg. no. 556724-1616 (the "Company"), are hereby given notice to attend the Extraordinary General Meeting to be held on 15 November 2024, at 10:00 CET at Advokatfirman Schjødt at Hamngatan 27 in Stockholm. Registration for the meeting begins at 09:30 CET. Right to participate in the general meetingShareholders wishing to attend the Extraordinary

Elkem ASA - Invitation to third quarter 2024 results presentation

Oslo, 16 October 2024 Elkem ASA will release its report for the third quarter 2024 on Thursday, 24 October at 7.00 a.m. CET. The quarterly report and presentation material will be made available at this time at www.elkem.com In connection with the quarterly report, the company will host a presentation at 9.00 a.m. CET. The event will take place in Auditoriet, Haakon Vll gate 2, Oslo. The third quarter presentation can also be viewed in a live webcast at Elkem Webcast 3Q 2024 (royalcast.com)  or via www.elkem.com

Invitation to conference call, October 23 at 16:00 (CET)

Studsvik AB presents its Interim Report for the Third Quarter 2024 and hereby invites media and analysts to a conference call held in English on Wednesday, October 23 at 16:00 (CET).Studsvik’s Interim Report for the Third Quarter 2024 will be distributed at approximately 11:30 am (CET), October 23. As of this time, the report will also be available at www.studsvik.com. The call will be held in English, starting 16:00 (CET). If you wish to participate via webcast please use the link below. Via the webcast you are able to ask written questions. Studsvik Q3 Report 2024 (

Safello enters into an agreement with Trustly

Stockholm 16 October 2024 | Safello, the leading cryptocurrency exchange in the Nordics, has entered into an agreement and a strategic partnership with Trustly, the global leader in account-to-account payments. Through this collaboration, Safello will integrate Trustly’s direct bank payment solution, enabling users to make instant payments in SEK and EUR, providing another seamless way to buy crypto on the platform. Trustly, founded in 2008, offers a secure and efficient direct payment system that seamlessly connects users’ bank accounts with online services. By integrating Trustly’s

Publishing of Valmet's Interim Review January – September 2024 on October 30, 2024

Valmet Oyj’s press release on October 16, 2024 at 9:30 a.m. EESTValmet’s Interim Review January – September 2024 will be published on Wednesday, October 30, 2024, at approximately 2:00 p.m. Finnish time (EEST). The stock exchange release and presentation material in English and in Finnish will be available at that time on Valmet's website at www.valmet.com/investors.  Webcast  Valmet will arrange a news conference in English as a live webcast at https://valmet.videosync.fi/q3-2024 on Wednesday, October 30, 2024, at 3:00 p.m. Finnish time (EEST). President and CEO Thomas Hinnerskov and

Inhalation Sciences provides latest status update on ongoing FDA BAA dissolution research project

(Stockholm, 16 October 2024) Inhalation Sciences Sweden AB (ISAB) today releases the latest update on progress in its FDA BAA (Broad Agency Agreement) dissolution collaborative research project evaluating the discriminative power of ISAB’s DissolvIt[®] in comparing drug formulations aimed for administration via inhalation. The project - contract number 75F40122C00197 - was communicated by ISAB on September 15[th], 2022, with updates throughout 2023.ISAB today announces that the deadline for the formal completion of its FDA BAA project has been extended by six months, with an updated

Neste MY Renewable Diesel to power Verne data centers’ back-up generators in Finland

Neste Corporation, Press release, 16 October 2024 at 9 a.m. (EET) Photo: Neste MY Renewable Diesel truck in front of Verne's data center in Helsinki. Source: VerneNeste’s renewable diesel helps Verne, a provider of sustainable data center solutions for high intensity computing, to transition its operations from fossil to renewable fuels. Verne's data centers in Helsinki, Pori and Tampere in Finland will use Neste MY Renewable Diesel™  to power their backup generators. The switch from

Oriola Corporation to publish its Interim Report for January-September 2024 on 30 October 2024

Oriola Corporation  Investor news  16 October 2024 at 9:00 a.m. EEST Oriola Corporation to publish its Interim Report for January-September 2024 on 30 October 2024 Oriola Corporation will publish its Interim Report for January-September 2024 on Wednesday 30 October 2024 at around 8:30 a.m. EEST. The Interim Report will be available on Oriola’s website after the publication. Welcome to join our results presentation CEO Katarina Gabrielson and CFO Mats Danielsson will present the Q3 results at a webcast meeting on the same day starting at 10.00 a.m. EEST. The link to the webcast

SKF to publish Q3 report on 30 October

Gothenburg, 16 October 2024: SKF will publish its Q3 results for 2024 on 30 October at approximately 07:00 (CET). Investors, analysts and media are invited to join a webcast, which will be held in English, at 08:00 (CET). To join the webcast, please login at least 10 minutes before the start using the below link or phone numbers:Link to web event: https://www.investis-live.com/skf/6703fe36b2cedb000e390899/aherus  Sweden: +46 8 5051 0031UK / International: +44 207 107 0613 All information regarding the results will be made available on the Group’s IR website: https://investors.

Cereno Scientific to attend BIO-Europe in Stockholm, November 4–6, 2024

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that the Company will attend BIO-Europe in Stockholm, November 4–6, 2024.Sten R. Sörensen, CEO, will participate at the well-attended partnering event that attracts global business leaders including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts.  About BIO-Europe BIO-Europe is the largest partnering event in

Arctic Bioscience – Presentation for today’s webcast

With reference to yesterday’s stock exchange release regarding webcast to be hosted today at 12:00 CET to present the results from the HeROPA read-out.Attached is the presentation material which will be presented at this webcast. The webcast will be hosted by CEO Christer L. Valderhaug and Medical Director Runhild Gammelsæter. Webcast details: Date: Wednesday 16[th] of October 2024 Time: 12:00 CET Format: Webcast Language: English The presentation can be accessed through the link below: Link: https://channel.royalcast.com/landingpage/hegnarmedia/20241016_1/ This

There are no items matching the current filter
There are no more items matching the current filter
Back to top